A small biopharmaceutical company in Raleigh is moving its lead drug candidate into clinical trials after closing a $36 million funding round.
The financing provides Aer Therapeutics with a multi-year runway that will cover at least two clinical studies, including a phase 1 trial set to begin this year, as it evaluates an inhaled treatment for patients of chronic obstructive pulmonary disease.
Aer began its fundraising efforts in the first half of 2022, before funding for life sciences companies…
